Focus: DiaMedica Therapeutics is a public biotech company developing biologic therapeutics for neurology, nephrology, and metabolic diseases. The company is pre-revenue and focused on advancing a pipeline of recombinant protein and small molecule programs through early-stage clinical development.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow DiaMedica Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for DiaMedica Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from DiaMedica Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview - TradingView
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview TradingView
MSN Money - MSN
MSN Money MSN
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - Business Wire
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 Business Wire
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of "Moderate Buy" from Brokerages MarketBeat
DMAC DiaMedica Therapeutics Inc. reports narrower Q4 2025 loss than consensus forecasts, its stock rises modestly in today’s trading. - Verified Stock Signals - Newser
DMAC DiaMedica Therapeutics Inc. reports narrower Q4 2025 loss than consensus forecasts, its stock rises modestly in today’s trading. - Verified Stock Signals Newser
DMAC DiaMedica Therapeutics Inc. reports narrower Q4 2025 loss than consensus forecasts, its stock rises modestly in today’s trading. - Expert Entry Points - Newser
DMAC DiaMedica Therapeutics Inc. reports narrower Q4 2025 loss than consensus forecasts, its stock rises modestly in today’s trading. - Expert Entry Points Newser
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo